$MLTX
MoonLake Immunotherapeutics Stock $mltx

$mltx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000182158624000008 Filed on February 29, 2024

Income Statement

Concept	2023 Q4	2023
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.931M	$22.32M
YoY Change	30.11%	-3.0%
% of Gross Profit
Research & Development	$8.098M	$31.80M
YoY Change	-28.77%	-24.37%
% of Gross Profit
Depreciation & Amortization	$3.290K	$13.16K
YoY Change	0.0%	6.47%
% of Gross Profit
Operating Expenses	$15.03M	$54.12M
YoY Change	-9.99%	-16.81%
Operating Profit		-$54.12M
YoY Change		-16.81%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$7.186M	$10.14M
YoY Change	2900.21%	1613.34%
Pretax Income	-$7.843M	-$43.98M
YoY Change	-52.34%	-31.77%
Income Tax	$44.31K	$94.39K
% Of Pretax Income
Net Earnings	-$7.437M	-$36.01M
YoY Change	284.32%	-27.95%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.73
Diluted Earnings Per Share	-$0.12	-$0.73
COMMON SHARES
Basic Shares Outstanding		49.12M shares
Diluted Shares Outstanding		49.12M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$511.0M	$511.0M
YoY Change	608.69%	608.6%
Cash & Equivalents	$451.2M	$451.2M
Short-Term Investments	$59.84M	$59.84M
Other Short-Term Assets	$112.0K	$112.0K
YoY Change	-47.52%	-47.52%
Inventory
Prepaid Expenses	$2.102M
Receivables
Other Receivables	$1.057M
Total Short-Term Assets	$514.2M	$514.2M
YoY Change	572.01%	572.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$320.9K	$3.949M
YoY Change	549.67%	1089.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.423M	$8.423M
YoY Change
Total Long-Term Assets	$12.37M	$12.37M
YoY Change	3627.1%	3627.09%
TOTAL ASSETS
Total Short-Term Assets	$514.2M	$514.2M
Total Long-Term Assets	$12.37M	$12.37M
Total Assets	$526.5M	$526.5M
YoY Change	585.21%	585.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.465M	$1.465M
YoY Change	959.99%	959.99%
Accrued Expenses	$8.128M	$8.128M
YoY Change	9.68%	9.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.966M	$9.966M
YoY Change	30.01%	30.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.083M	$3.083M
YoY Change	649.93%	649.93%
Total Long-Term Liabilities	$3.083M	$3.083M
YoY Change	649.94%	649.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.966M	$9.966M
Total Long-Term Liabilities	$3.083M	$3.083M
Total Liabilities	$13.05M	$30.86M
YoY Change	61.57%	10.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.7M
YoY Change	44.65%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$495.7M	$495.7M
YoY Change
Total Liabilities & Shareholders Equity	$526.5M	$526.5M
YoY Change	585.21%	585.21%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$7.437M	-$36.01M
YoY Change	284.32%	-27.95%
Depreciation, Depletion And Amortization	$3.290K	$13.16K
YoY Change	0.0%	6.47%
Cash From Operating Activities	-$12.34M	-$42.78M
YoY Change	6.45%	-23.47%
INVESTING ACTIVITIES
Capital Expenditures	$284.6K	$284.6K
YoY Change		1677.96%
Acquisitions
YoY Change
Other Investing Activities	$117.2M	-$24.90M
YoY Change	1083.17%	-22.97%
Cash From Investing Activities	$116.9M	-$25.18M
YoY Change	1080.3%	-22.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	28.42M	$479.7M
YoY Change	747700.53%	300.78%
NET CHANGE
Cash From Operating Activities	-12.34M	-$42.78M
Cash From Investing Activities	116.9M	-$25.18M
Cash From Financing Activities	28.42M	$479.7M
Net Change In Cash	132.9M	$411.7M
YoY Change	-7962.76%	1208.25%
FREE CASH FLOW
Cash From Operating Activities	-$12.34M	-$42.78M
Capital Expenditures	$284.6K	$284.6K
Free Cash Flow	-$12.63M	-$43.06M
YoY Change	8.91%	-22.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	us-gaap	Depreciation Depreciation	12358	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	9654778	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	150833021	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	284634	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25184324	usd
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001821586
CY2023	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2023#OtherNonoperatingIncome
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39630
CY2023	dei	Entity Registrant Name EntityRegistrantName	MOONLAKE IMMUNOTHERAPEUTICS
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1711963
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	Dorfstrasse 29
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6300
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Zug
CY2023	dei	Entity Address Country EntityAddressCountry	CH
CY2023	dei	City Area Code CityAreaCode	41
CY2023	dei	Local Phone Number LocalPhoneNumber	415108022
CY2023	dei	Security12b Title Security12bTitle	Class A ordinary share, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	MLTX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1120000000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	Mountain View, CA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39505627	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	59838900	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32609108	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1056862	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	217129	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2102203	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4179468	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	514167302	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	76511332	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3628480	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282580	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320865	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49389	usd
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1120000000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	Mountain View, CA
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	451169337	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39505627	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	59838900	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32609108	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1056862	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	217129	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2102203	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4179468	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	514167302	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	76511332	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3628480	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282580	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	320865	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49389	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	8423468	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12372813	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	331969	usd
CY2023Q4	us-gaap	Assets Assets	526540115	usd
CY2022Q4	us-gaap	Assets Assets	76843301	usd
CY2023Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1837684	usd
CY2022Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	254972	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1197876	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153629	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6930120	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7256845	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9965680	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7665446	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2499990	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	128951	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	583426	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	282206	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3083416	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	8423468	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12372813	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	331969	usd
CY2023Q4	us-gaap	Assets Assets	526540115	usd
CY2022Q4	us-gaap	Assets Assets	76843301	usd
CY2023Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1837684	usd
CY2022Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	254972	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1197876	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153629	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6930120	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7256845	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9965680	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7665446	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2499990	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	128951	usd
CY2023Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	583426	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	282206	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3083416	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13049096	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8076603	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	609969236	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129192291	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116657472	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80650212	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2357621	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	350946	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	495675683	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48898296	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	17815336	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	19868402	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	513491019	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	526540115	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31801880	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22321216	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23012463	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	65061417	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-65061417	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10138367	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	591732	usd
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-43984729	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-64469685	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94388	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36366	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-44079117	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-64506051	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-36007260	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-49973249	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8071857	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14532802	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	411157	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13049096	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8076603	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	609969236	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129192291	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116657472	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80650212	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2357621	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	350946	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	17815336	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	19868402	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	513491019	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	526540115	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76843301	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31801880	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42048954	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22321216	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23012463	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	54123096	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	65061417	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-54123096	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-65061417	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	10138367	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	591732	usd
CY2023	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-43984729	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-64469685	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94388	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36366	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-44079117	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-64506051	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-36007260	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-49973249	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8071857	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14532802	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2330101	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	390753	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-336579	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	269893	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34511723	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49437461	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7573872	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-14407944	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2022	mnlk	Noncontrolling Interest Decrease From Reverse Recapitalization NoncontrollingInterestDecreaseFromReverseRecapitalization	0	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	134653204	usd
CY2022	mnlk	Adjustments To Additional Paid In Capital Emission Fee Reimbursement AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement	-56240	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	9658568	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-64506051	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	660646	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34511723	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-7573872	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2022	mnlk	Noncontrolling Interest Decrease From Reverse Recapitalization NoncontrollingInterestDecreaseFromReverseRecapitalization	0	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	134653204	usd
CY2022	mnlk	Adjustments To Additional Paid In Capital Emission Fee Reimbursement AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement	-56240	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	9658568	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-64506051	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2023	mnlk	Noncontrolling Interest Increase From Capital Injection In Subsidiary NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary	-2750515	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	7106005	usd
CY2023	mnlk	Adjustments To Additional Paid In Capital Stamp Duty Fees AdjustmentsToAdditionalPaidInCapitalStampDutyFees	0	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-44079117	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1993522	usd
CY2023	us-gaap	Depreciation Depreciation	13158	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7106005	usd
CY2023	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	-85254	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-484762	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-220880	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	839733	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	68355	usd
CY2023	mnlk	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	65513	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6346203	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1582712	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-222259	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-152425	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2685576	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42778167	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55893900	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	175732711	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	42226021	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9901437	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16009	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32340593	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	482454426	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023	mnlk	Payments Of Stamp Duty PaymentsOfStampDuty	2752918	usd
CY2022	mnlk	Payments Of Stamp Duty PaymentsOfStampDuty	0	usd
CY2023	mnlk	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	0	usd
CY2022	mnlk	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	134646009	usd
CY2022	mnlk	Proceeds From Contribution From Par Value Of Common Stock ProceedsFromContributionFromParValueOfCommonStock	42935	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3791	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	479701508	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119692735	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-75307	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8540	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	482454426	usd
CY2023	mnlk	Noncontrolling Interest Increase From Capital Injection In Subsidiary NoncontrollingInterestIncreaseFromCapitalInjectionInSubsidiary	-2750515	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	7106005	usd
CY2023	mnlk	Adjustments To Additional Paid In Capital Stamp Duty Fees AdjustmentsToAdditionalPaidInCapitalStampDutyFees	0	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-44079117	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1993522	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	513491019	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-44079117	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-64506051	usd
CY2023	us-gaap	Depreciation Depreciation	13158	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7106005	usd
CY2023	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	-85254	usd
CY2022	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	304031	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-484762	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-220880	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	839733	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	68355	usd
CY2023	mnlk	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	65513	usd
CY2022	mnlk	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6346203	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2730373	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1582712	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1314318	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-222259	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-152425	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-326725	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2685576	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55893900	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	42226021	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9901437	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16009	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023	mnlk	Payments Of Stamp Duty PaymentsOfStampDuty	2752918	usd
CY2022	mnlk	Payments Of Stamp Duty PaymentsOfStampDuty	0	usd
CY2022	mnlk	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	134646009	usd
CY2023	mnlk	Proceeds From Contribution From Par Value Of Common Stock ProceedsFromContributionFromParValueOfCommonStock	0	usd
CY2022	mnlk	Proceeds From Contribution From Par Value Of Common Stock ProceedsFromContributionFromParValueOfCommonStock	42935	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3791	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	479701508	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119692735	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-75307	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8540	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	411663710	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	411663710	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31466782	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39505627	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8038845	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	451169337	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	41713	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4312	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3637545	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	435005	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	422519	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	155552	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15000000.0	usd
CY2022Q2	mnlk	Investments Acquired Through Reverse Recapitalization InvestmentsAcquiredThroughReverseRecapitalization	115051000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	80842000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	116000000	usd
CY2022Q2	mnlk	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	15520000	usd
CY2022Q2	mnlk	Reverse Recapitalization Accrued Expenses ReverseRecapitalizationAccruedExpenses	5798000	usd
CY2022Q2	mnlk	Reverse Recapitalization Other Transaction Expenses ReverseRecapitalizationOtherTransactionExpenses	5697000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134689000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52701111	shares
CY2022Q2	mnlk	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	33.638698
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in estimating the fair value of share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.</span></div>
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	325317	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31466782	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39505627	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8038845	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	451169337	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39505627	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	41713	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4312	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3637545	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	435005	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	422519	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	155552	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15000000.0	usd
CY2022Q2	mnlk	Investments Acquired Through Reverse Recapitalization InvestmentsAcquiredThroughReverseRecapitalization	115051000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	80842000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	116000000	usd
CY2022Q2	mnlk	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	15520000	usd
CY2022Q2	mnlk	Reverse Recapitalization Accrued Expenses ReverseRecapitalizationAccruedExpenses	5798000	usd
CY2022Q2	mnlk	Reverse Recapitalization Deferred Initial Public Offering Underwriting Fees ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees	4025000	usd
CY2022Q2	mnlk	Reverse Recapitalization Other Transaction Expenses ReverseRecapitalizationOtherTransactionExpenses	5697000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134689000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52701111	shares
CY2022Q2	mnlk	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	33.638698
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in estimating the fair value of share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.</span></div>
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	186514788	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	151493	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in large financial institutions which, at times, may exceed the CHF 100,000 deposit protection limit in Switzerland, the $250,000 Federal Deposit Insurance Corporation deposit insurance coverage limit in the United States, the GBP 85,000 Financial Services Compensation Scheme deposit protection limit in the United Kingdom, or the €100,000 Fundo de Garantia de Depósitos deposit protection limit in Portugal. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. Additionally, the Company ensures further protection against credit risk by diversifying its cash holdings across a variety of credit institutions, thereby minimizing the potential impact of any adverse events on a single institution. Further, the Company's investment strategy for cash (in excess of current business requirements) is set to invest in short-term marketable debt securities. Management actively monitors credit risk in the investment portfolio. Credit risk exposures are controlled in accordance with policies approved by the board of directors to identify, measure, monitor and control credit risks.</span></div>
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	151493	usd
CY2023	mnlk	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2023	us-gaap	Profit Loss ProfitLoss	-44100000	usd
CY2023Q4	mnlk	Current Assets In Excess Of Current Liabilities CurrentAssetsInExcessOfCurrentLiabilities	504200000	usd
CY2023Q4	us-gaap	Cash Cash	451200000	usd
CY2023	mnlk	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2023	us-gaap	Profit Loss ProfitLoss	-44100000	usd
CY2023Q4	mnlk	Current Assets In Excess Of Current Liabilities CurrentAssetsInExcessOfCurrentLiabilities	504200000	usd
CY2023Q4	us-gaap	Cash Cash	451200000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	189235642	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	52490507	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	189235642	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	52490507	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	186514788	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2720854	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	189235642	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	52099754	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	390753	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52490507	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2720854	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	189235642	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	52099754	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	390753	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52490507	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1077478	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1416597	usd
CY2023Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	842729	usd
CY2022Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	2443863	usd
CY2023Q4	mnlk	Other Prepaid Consulting And Advisory Fees Current OtherPrepaidConsultingAndAdvisoryFeesCurrent	70018	usd
CY2022Q4	mnlk	Other Prepaid Consulting And Advisory Fees Current OtherPrepaidConsultingAndAdvisoryFeesCurrent	105651	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	111978	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	213357	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2102203	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4179468	usd
CY2023Q4	mnlk	Supply And Manufacturing Expense Noncurrent SupplyAndManufacturingExpenseNoncurrent	8423468	usd
CY2022Q4	mnlk	Supply And Manufacturing Expense Noncurrent SupplyAndManufacturingExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	8423468	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1077478	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1416597	usd
CY2023Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	842729	usd
CY2022Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	2443863	usd
CY2023Q4	mnlk	Other Prepaid Consulting And Advisory Fees Current OtherPrepaidConsultingAndAdvisoryFeesCurrent	70018	usd
CY2022Q4	mnlk	Other Prepaid Consulting And Advisory Fees Current OtherPrepaidConsultingAndAdvisoryFeesCurrent	105651	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	111978	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	213357	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2102203	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4179468	usd
CY2023Q4	mnlk	Supply And Manufacturing Expense Noncurrent SupplyAndManufacturingExpenseNoncurrent	8423468	usd
CY2022Q4	mnlk	Supply And Manufacturing Expense Noncurrent SupplyAndManufacturingExpenseNoncurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	8423468	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	0	usd
CY2023Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	911454	usd
CY2022Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	31687	usd
CY2023Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	553459	usd
CY2022Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	65979	usd
CY2023Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	108249	usd
CY2022Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	0	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	264522	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	157306	usd
CY2023Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1837684	usd
CY2022Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	254972	usd
CY2023Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	911454	usd
CY2022Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	31687	usd
CY2023Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	553459	usd
CY2022Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	65979	usd
CY2023Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	108249	usd
CY2022Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	0	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	264522	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	157306	usd
CY2023Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1837684	usd
CY2022Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	254972	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2780219	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1109734	usd
CY2023Q4	mnlk	Accrued Supply And Manufacturing Fees Current AccruedSupplyAndManufacturingFeesCurrent	1603739	usd
CY2022Q4	mnlk	Accrued Supply And Manufacturing Fees Current AccruedSupplyAndManufacturingFeesCurrent	0	usd
CY2023Q4	mnlk	Accrued Research And Development Services And License Fees Current AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent	1226281	usd
CY2022Q4	mnlk	Accrued Research And Development Services And License Fees Current AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent	5803432	usd
CY2023Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	853905	usd
CY2022Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	218021	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	367976	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	109826	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	98000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	15832	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6930120	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7256845	usd
CY2023Q4	mnlk	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	period
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2780219	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1109734	usd
CY2023Q4	mnlk	Accrued Supply And Manufacturing Fees Current AccruedSupplyAndManufacturingFeesCurrent	1603739	usd
CY2022Q4	mnlk	Accrued Supply And Manufacturing Fees Current AccruedSupplyAndManufacturingFeesCurrent	0	usd
CY2023Q4	mnlk	Accrued Research And Development Services And License Fees Current AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent	1226281	usd
CY2022Q4	mnlk	Accrued Research And Development Services And License Fees Current AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent	5803432	usd
CY2023Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	853905	usd
CY2022Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	218021	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	367976	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	109826	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	98000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	15832	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6930120	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7256845	usd
CY2023Q4	mnlk	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	2	period
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P39M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P22M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.049
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.008
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1343255	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1343255	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1029249	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	95794	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	95794	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	65923	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3973270	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	275404	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3697866	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1197876	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2499990	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	399882	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P39M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P22M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.049
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.008
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1343255	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1343255	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1029249	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	95794	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	95794	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	65923	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3973270	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	275404	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3697866	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1197876	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2499990	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	399882	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	155552	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1321969	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1322874	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	122698	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	451075	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	30639	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	5056	usd
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	200424	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	138243	usd
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-487991	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	374317	usd
CY2023	mnlk	Defined Benefit Plan Benefit Obligation Benefits Paid Net Of Adjustments DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments	229902	usd
CY2022	mnlk	Defined Benefit Plan Benefit Obligation Benefits Paid Net Of Adjustments DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments	-204695	usd
CY2023	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-208608	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	16267	usd
CY2023	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	-107750	usd
CY2022	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	0	usd
CY2023Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	2494481	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1321969	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1039763	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1083014	usd
CY2022	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	15522	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	155552	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1321969	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1322874	usd
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	122698	usd
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	451075	usd
CY2023	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	30639	usd
CY2022	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	5056	usd
CY2023	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	200424	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	138243	usd
CY2023	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-487991	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	374317	usd
CY2023	mnlk	Defined Benefit Plan Benefit Obligation Benefits Paid Net Of Adjustments DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments	229902	usd
CY2022	mnlk	Defined Benefit Plan Benefit Obligation Benefits Paid Net Of Adjustments DefinedBenefitPlanBenefitObligationBenefitsPaidNetOfAdjustments	-204695	usd
CY2023	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-208608	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	16267	usd
CY2023	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	-107750	usd
CY2022	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	0	usd
CY2023Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	2494481	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1321969	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1039763	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1083014	usd
CY2023	us-gaap	Defined Benefit Plan Expected Return On Plan Assets DefinedBenefitPlanExpectedReturnOnPlanAssets	36523	usd
CY2023	mnlk	Defined Benefit Plan Plan Assets Increase Decrease For Return Above Expected Returns DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns	48938	usd
CY2022	mnlk	Defined Benefit Plan Plan Assets Increase Decrease For Return Above Expected Returns DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns	-115877	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200424	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	138243	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	200424	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	138243	usd
CY2023	mnlk	Defined Benefit Plan Plan Assets Benefits Paid Net Of Adjustments DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments	229902	usd
CY2022	mnlk	Defined Benefit Plan Plan Assets Benefits Paid Net Of Adjustments DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments	-204695	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	155082	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-14687	usd
CY2023Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1911056	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1039763	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1911056	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1039763	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent	2494481	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent	1321969	usd
CY2023Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-583425	usd
CY2022Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-282206	usd
CY2022Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Inflation DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation	0.0180
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0230
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0230
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	122698	usd
CY2023Q4	mnlk	Shares Authorized SharesAuthorized	600000000	shares
CY2023	mnlk	Defined Benefit Plan Plan Assets Increase Decrease For Return Above Expected Returns DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns	48938	usd
CY2022	mnlk	Defined Benefit Plan Plan Assets Increase Decrease For Return Above Expected Returns DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns	-115877	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200424	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	138243	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	200424	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	138243	usd
CY2023	mnlk	Defined Benefit Plan Plan Assets Benefits Paid Net Of Adjustments DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments	229902	usd
CY2022	mnlk	Defined Benefit Plan Plan Assets Benefits Paid Net Of Adjustments DefinedBenefitPlanPlanAssetsBenefitsPaidNetOfAdjustments	-204695	usd
CY2023	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	155082	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-14687	usd
CY2023Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1911056	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1039763	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1911056	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1039763	usd
CY2023Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent	2494481	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent	1321969	usd
CY2023Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-583425	usd
CY2022Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-282206	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	101716	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-168177	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-444329	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	268076	usd
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	-1817	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	-107750	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	0	usd
CY2023Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-234863	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	101716	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0135
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0220
CY2023Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets	0.0300
CY2022Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets	0.0380
CY2023Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Inflation DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation	0.0180
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	101716	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-168177	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-444329	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	268076	usd
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	-1817	usd
CY2023	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	-107750	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plan Net Prior Service Cost Credit Arising During Period Before Tax OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax	0	usd
CY2023Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-234863	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	101716	usd
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0135
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0220
CY2023Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets	0.0300
CY2022Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets	0.0380
CY2023Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Inflation DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation	0.0180
CY2022Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Inflation DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation	0.0180
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0230
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0230
CY2023	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	122698	usd
CY2022Q4	mnlk	Shares Authorized SharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	52701111	shares
CY2022Q4	mnlk	Shares Authorized SharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	52701111	shares
CY2023Q4	mnlk	Shares Authorized SharesAuthorized	600000000	shares
CY2023Q4	us-gaap	Shares Issued SharesIssued	62971929	shares
CY2023Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	544894	shares
CY2023Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	15200000	usd
CY2023Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	525924	shares
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	31700000	usd
CY2023Q3	mnlk	Sale Of Stock Stamp Duty Tax SaleOfStockStampDutyTax	-2800000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-36007260	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-49973249	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49122534	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49122534	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49122534	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49122534	shares
CY2023Q4	us-gaap	Shares Issued SharesIssued	62971929	shares
CY2023Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	544894	shares
CY2023Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	15200000	usd
CY2023Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	525924	shares
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	31700000	usd
CY2023Q3	mnlk	Sale Of Stock Stamp Duty Tax SaleOfStockStampDutyTax	-2800000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-36007260	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-49973249	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49122534	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49122534	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49122534	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49122534	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361353	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7100000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361353	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7100000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7106005	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9654778	usd
CY2023Q4	mnlk	Number Of Co Founders NumberOfCoFounders	3	co-founder
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7106005	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9654778	usd
CY2023Q4	mnlk	Number Of Co Founders NumberOfCoFounders	3	co-founder
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
CY2021	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-43469946	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-62115251	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-514783	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2354434	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43984729	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64469685	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-43469946	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-62115251	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-514783	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2354434	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43984729	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64469685	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.118
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.001
CY2023	mnlk	Effective Income Tax Rate Reconciliation Utilization Of Unrealized Loss Not Recognized In Prior Year Percent EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent	0.006
CY2022	mnlk	Effective Income Tax Rate Reconciliation Utilization Of Unrealized Loss Not Recognized In Prior Year Percent EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.123
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.014
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.005
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4493559	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4492435	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	69173	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	33451	usd
CY2023Q4	mnlk	Deferred Tax Assets Lease Liabililties DeferredTaxAssetsLeaseLiabililties	56527	usd
CY2022Q4	mnlk	Deferred Tax Assets Lease Liabililties DeferredTaxAssetsLeaseLiabililties	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.118
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.001
CY2023	mnlk	Effective Income Tax Rate Reconciliation Utilization Of Unrealized Loss Not Recognized In Prior Year Percent EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent	0.006
CY2022	mnlk	Effective Income Tax Rate Reconciliation Utilization Of Unrealized Loss Not Recognized In Prior Year Percent EffectiveIncomeTaxRateReconciliationUtilizationOfUnrealizedLossNotRecognizedInPriorYearPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.005
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.100
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.123
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.014
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.005
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4493559	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4492435	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	69173	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	33451	usd
CY2023Q4	mnlk	Deferred Tax Assets Lease Liabililties DeferredTaxAssetsLeaseLiabililties	56527	usd
CY2022Q4	mnlk	Deferred Tax Assets Lease Liabililties DeferredTaxAssetsLeaseLiabililties	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6715534	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7210383	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11334793	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11736269	usd
CY2023Q4	mnlk	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	55862	usd
CY2022Q4	mnlk	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	55862	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	usd
CY2023Q4	mnlk	Deferred Tax Assets Net Including Valuation Allowance DeferredTaxAssetsNetIncludingValuationAllowance	11278931	usd
CY2022Q4	mnlk	Deferred Tax Assets Net Including Valuation Allowance DeferredTaxAssetsNetIncludingValuationAllowance	11736269	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11278931	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11736269	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6715534	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7210383	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11334793	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11736269	usd
CY2023Q4	mnlk	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	55862	usd
CY2022Q4	mnlk	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	0	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	55862	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	usd
CY2023Q4	mnlk	Deferred Tax Assets Net Including Valuation Allowance DeferredTaxAssetsNetIncludingValuationAllowance	11278931	usd
CY2022Q4	mnlk	Deferred Tax Assets Net Including Valuation Allowance DeferredTaxAssetsNetIncludingValuationAllowance	11736269	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11278931	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11736269	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11300000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	56600000	usd
CY2023Q4	mnlk	Unrecognized Commitments And Contingencies UnrecognizedCommitmentsAndContingencies	44200000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3949345	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	331969	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11300000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11300000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	56600000	usd
CY2023Q4	mnlk	Unrecognized Commitments And Contingencies UnrecognizedCommitmentsAndContingencies	44200000	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3949345	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	331969	usd

Files In Submission

Name	View Source	Status
0001821586-24-000008-index-headers.html	Edgar Link	pending
0001821586-24-000008-index.html	Edgar Link	pending
0001821586-24-000008.txt	Edgar Link	pending
0001821586-24-000008-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mltx-exhibit41.htm	Edgar Link	pending
mltx_2023q4xex311dasilva.htm	Edgar Link	pending
mltx_2023q4xex312bodenstedt.htm	Edgar Link	pending
mltx_2023q4xex321dasilva.htm	Edgar Link	pending
mltx_2023q4xex322bodenstedt.htm	Edgar Link	pending
mltx_ex211subsidiarieslist.htm	Edgar Link	pending
mltx_ex231consentofindepen.htm	Edgar Link	pending
mltx_ex971-clawbackpolicy.htm	Edgar Link	pending
mnlk-20231231.htm	Edgar Link	pending
mnlk-20231231.xsd	Edgar Link	pending
mnlk-20231231_g1.jpg	Edgar Link	pending
mnlk-20231231_g2.jpg	Edgar Link	pending
mnlk-20231231_g3.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
mnlk-20231231_def.xml	Edgar Link	unprocessable
mnlk-20231231_lab.xml	Edgar Link	unprocessable
mnlk-20231231_pre.xml	Edgar Link	unprocessable
mnlk-20231231_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
mnlk-20231231_cal.xml	Edgar Link	unprocessable
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLTX
MoonLake Immunotherapeutics Stock $mltx

2023 Q4 Form 10-K Financial Statement

#000182158624000008 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLTX MoonLake Immunotherapeutics Stock $mltx

2023 Q4 Form 10-K Financial Statement

#000182158624000008 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLTX
MoonLake Immunotherapeutics Stock $mltx